- Home
- BSX
as 07-26-2024 4:00pm EST
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
| Founded: | 1979 | Country: | United States |
| Employees: | N/A | City: | MARLBOROUGH |
| Market Cap: | 109.2B | IPO Year: | 1992 |
| Target Price: | $84.33 | AVG Volume (30 days): | 6.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.19 | EPS Growth: | 101.69 |
| 52 Week Low/High: | $48.35 - $79.43 | Next Earning Date: | 07-24-2024 |
| Revenue: | $14,707,000,000 | Revenue Growth: | 12.74% |
| Revenue Growth (this year): | 13.48% | Revenue Growth (next year): | 10.13% |
Stock Insider Trading Activity of Boston Scientific Corporation (BSX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carruthers Wendy | BSX | EVP, Human Resources | Jul 1 '24 | Sell | $77.30 | 6,983 | $539,785.90 | 42,908 | SEC Form 4 |
| Carruthers Wendy | BSX | EVP, Human Resources | Jun 3 '24 | Sell | $75.33 | 6,983 | $526,029.39 | 45,628 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | May 29 '24 | Sell | $75.10 | 63,802 | $4,791,447.26 | 28,022 | SEC Form 4 |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | May 28 '24 | Sell | $75.34 | 14,011 | $1,055,590.14 | 20,197 | SEC Form 4 |
| Brennan Daniel J. | BSX | EVP and CFO | May 22 '24 | Sell | $75.91 | 64,454 | $4,892,819.16 | 271,542 | SEC Form 4 |
| Brennan Daniel J. | BSX | EVP and CFO | May 22 '24 | Sell | $75.11 | 47,621 | $3,576,932.36 | 223,921 | SEC Form 4 |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | May 21 '24 | Sell | $75.60 | 18,037 | $1,363,606.22 | 32,326 | SEC Form 4 |
| Brown Vance R | BSX | SVP, GC and Corp. Secretary | May 21 '24 | Sell | $76.01 | 15,006 | $1,140,633.07 | 32,326 | SEC Form 4 |
| Sorenson John Bradley | BSX | EVP, Global Operations | May 1 '24 | Sell | $71.50 | 17,587 | $1,257,488.09 | 50,638 | SEC Form 4 |
| Carruthers Wendy | BSX | EVP, Human Resources | May 1 '24 | Sell | $71.47 | 6,983 | $499,075.01 | 48,348 | SEC Form 4 |
| LUDWIG EDWARD J | BSX | Director | Apr 26 '24 | Sell | $73.29 | 9,818 | $719,562.20 | 41,374 | SEC Form 4 |
| Sorenson John Bradley | BSX | EVP, Global Operations | Apr 1 '24 | Sell | $69.30 | 16,351 | $1,133,068.71 | 50,638 | SEC Form 4 |
| Carruthers Wendy | BSX | EVP, Human Resources | Apr 1 '24 | Sell | $68.42 | 6,983 | $477,776.86 | 51,068 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Mar 18 '24 | Sell | $66.45 | 14,506 | $963,929.50 | 58,098 | SEC Form 4 |
| Carruthers Wendy | BSX | EVP, Human Resources | Mar 1 '24 | Sell | $66.35 | 6,983 | $463,322.05 | 53,788 | SEC Form 4 |
| Butcher Arthur C | BSX | EVP& Grp Pres, MedSurg & APAC | Feb 26 '24 | Sell | $67.07 | 9,335 | $626,098.45 | 28,937 | SEC Form 4 |
| Carruthers Wendy | BSX | EVP, Human Resources | Feb 23 '24 | Sell | $66.89 | 6,983 | $467,092.87 | 56,508 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Feb 21 '24 | Sell | $66.35 | 4,960 | $329,096.00 | 72,604 | SEC Form 4 |
| Brennan Daniel J. | BSX | EVP and CFO | Feb 16 '24 | Sell | $65.86 | 13,662 | $899,779.32 | 271,542 | SEC Form 4 |
| LUDWIG EDWARD J | BSX | Director | Feb 13 '24 | Sell | $65.03 | 7,000 | $455,223.30 | 41,374 | SEC Form 4 |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Jan 12 '24 | Sell | $60.00 | 11,660 | $699,600.00 | 173,472 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Jan 9 '24 | Sell | $59.25 | 15,172 | $898,941.00 | 56,588 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Jan 4 '24 | Sell | $58.40 | 15,000 | $876,001.50 | 56,588 | SEC Form 4 |
| Mirviss Jeffrey B. | BSX | EVP&Pres, Periph Intervent | Jan 3 '24 | Sell | $57.82 | 11,931 | $689,862.35 | 56,588 | SEC Form 4 |
| Fitzgerald Joseph Michael | BSX | EVP & Group Pres, Cardiology | Dec 29 '23 | Sell | $57.50 | 81,940 | $4,711,550.00 | 174,241 | SEC Form 4 |
Latest Boston Scientific Corporation News
BSX Breaking Stock News: Dive into BSX Ticker-Specific Updates for Smart Investing
Zacks
7 hours ago
Integer Holdings (ITGR) Q2 Earnings Top Estimates, Margins Up
Zacks
7 hours ago
3 Reasons Why You Should Hold HealthEquity (HQY) Stock Now
Zacks
7 hours ago
Three Reasons to Retain Avanos (AVNS) Stock in Your Portfolio
MT Newswires
8 hours ago
UBS Adjusts Boston Scientific Price Target to $94 From $90, Maintains Buy Rating
Investor's Business Daily
9 hours ago
Stock Market Diverges, With Tesla, Google, ServiceNow, GE In Focus: Weekly Review
Simply Wall St.
13 hours ago
Boston Scientific Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
MT Newswires
a day ago
Boston Scientific's 'Solid' New 2024 Guidance Has Room for Upside, RBC Says
The Wall Street Journal
a day ago
S&P 500’s Biggest Loser Has a Heart Valve Problem
Compare BSX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BSX Boston Scientific Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.